<p>Syphilis cases are rising fast enough on Australia's Sunshine Coast that public health officials have gone public with a blunt warning: get tested, even if you feel completely fine. This isn't a localized blip — it fits a pattern playing out across multiple continents, and it directly affects anyone who is sexually active, including the MeetPositives community.</p>

<h2>What's Actually Happening on the Sunshine Coast</h2>

<p>Sunshine Coast Public Health issued an alert after a spike in confirmed syphilis diagnoses across the region. Officials aren't just urging people with symptoms to come in — they're calling on all sexually active adults to get screened, regardless of how they feel.</p>

<p>That distinction matters. Syphilis is a master of disguise. Its earliest stage often produces a single painless sore that disappears on its own within three to six weeks. Many people miss it entirely. By the time secondary symptoms arrive — rashes, flu-like illness, mouth sores — the infection has already been transmissible for weeks or months.</p>

<p>The <a href="https://www.cdc.gov/std/syphilis/stdfact-syphilis.htm" target="_blank" rel="noopener noreferrer">CDC's syphilis fact sheet</a> confirms that people with primary syphilis frequently don't seek care because the sore is painless and hidden in hard-to-see areas. The window between infection and awareness is exactly where transmission keeps happening.</p>

<h2>This Is Part of a Much Bigger Pattern</h2>

<p>The Sunshine Coast warning doesn't exist in isolation. The <a href="https://www.who.int/news-room/fact-sheets/detail/syphilis" target="_blank" rel="noopener noreferrer">World Health Organization estimates over 7.1 million new syphilis infections occurred globally in 2020</a> among adults aged 15–49 — and the trend lines since then have moved in the wrong direction.</p>

<p>In the United States, <a href="https://www.cdc.gov/std/statistics/2022/default.htm" target="_blank" rel="noopener noreferrer">CDC data from 2022 showed syphilis cases hit a 70-year high</a>, with over 207,000 reported cases. Congenital syphilis — passed from mother to newborn — rose 937% over a decade. These numbers aren't abstract: they represent real people who didn't know they were infected.</p>

<p>We've covered this pattern domestically before. When an <a href="https://meetpositives.com/blog/austin-clinic-free-sexual-health-care-texas-syphilis-surge">Austin clinic went free amid the Texas syphilis surge</a>, it was responding to exactly this kind of acceleration. Australia is now in the same position.</p>

<h2>Why People Living With Other STIs Should Pay Extra Attention</h2>

<p>If you're managing HSV, HIV, HPV, or hepatitis, syphilis deserves your specific attention — not because you're at higher risk simply from having another infection, but because co-infections complicate everything.</p>

<p>People living with HIV face a well-documented interaction with syphilis. Syphilis sores break down the skin barrier, which can increase HIV transmission risk. HIV can also alter syphilis test results and speed up disease progression if syphilis goes untreated. The relationship runs both ways.</p>

<blockquote>"Syphilis remains one of the most underdiagnosed STIs precisely because people feel well. Regular testing — at least annually for sexually active adults, more frequently for those with multiple partners — is the only reliable way to catch it early." — Queensland Health guidance, echoed by infectious disease specialists across Australia and globally.</blockquote>

<p>For anyone already navigating an STI diagnosis, adding a syphilis test to your routine screening isn't paranoia. It's sound health management. If you want a full picture of where STI rates currently stand across conditions, our <a href="https://meetpositives.com/blog/sti-statistics-facts-2026">2026 STI statistics breakdown</a> puts the numbers in context.</p>

<h2>Who Should Get Tested — and How Often</h2>

<p>Public health guidelines generally recommend annual syphilis testing for anyone sexually active with new or multiple partners. More frequent testing — every three to six months — applies if you're a man who has sex with men, if you're living with HIV, or if you or your partners use drugs that affect sexual decision-making.</p>

<p>Testing is simple: a blood draw, or sometimes a swab of an active sore. Results typically come back within a few days. Treatment, when caught early, is a single penicillin injection. Late-stage syphilis requires more intensive treatment but is still curable — unlike herpes or HIV, syphilis can be fully eliminated from the body with antibiotics.</p>

<p>At-home STI testing has expanded significantly, and it's worth knowing your options. Our piece on <a href="https://meetpositives.com/blog/the-growing-popularity-of-at-home-std-testing-what-health-experts-want-you-to-know">at-home STD testing and what health experts want you to know</a> runs through what works, what doesn't, and when you need an in-person visit anyway.</p>

<h2>The Disclosure and Testing Conversation You Might Need to Have</h2>

<p>A surge like this is a reasonable prompt to revisit conversations with partners about testing frequency. If you've been with someone new recently, or if it's been more than a year since your last full panel, this news from the Sunshine Coast is as good a reason as any to book an appointment this week.</p>

<p>Syphilis testing should be part of a standard full STI panel — alongside HIV, gonorrhea, chlamydia, and hepatitis B and C. Most sexual health clinics and general practitioners can order the full panel in one visit. Telehealth has made ordering lab work easier than ever if clinic access is limited in your area.</p>

<p>The broader point here: the MeetPositives community already understands that managing your sexual health is an ongoing practice, not a one-time event. You get that. A syphilis surge isn't cause for panic — it's cause for action. Book the test. Know your status. That's how you protect yourself and the people you care about.</p>

Condition Guides & Resources

Syphilis Surge: Why You Need a Test Right Now

<p>Texas reported one of the sharpest syphilis increases in the country last year — and now an Austin clinic is stepping up with something the public health system rarely offers without strings attached: completely free sexual health services. No insurance. No copay. No bureaucratic maze.</p>

<h2>What's Actually Happening in Texas</h2>
<p>Syphilis cases across Texas have been climbing for years, but recent data from the <a href="https://www.cdc.gov/std/statistics/2022/default.htm" target="_blank" rel="noopener noreferrer">CDC's National Overview of STIs</a> shows the state among the hardest hit in the South — a region that consistently carries a disproportionate share of the country's STI burden. In 2022 alone, primary and secondary syphilis cases nationally hit a 70-year high.</p>
<p>Congenital syphilis — passed from mother to newborn — is particularly alarming. The CDC reported a 937% increase in congenital syphilis cases nationally over the past decade. Texas has contributed significantly to that number.</p>

<h2>What the Austin Clinic Is Actually Offering</h2>
<p>The clinic, responding to this public health pressure, is providing free STI testing and treatment — including for syphilis — to anyone who walks in. That matters more than it might sound. Syphilis is entirely curable with penicillin when caught early, but it often goes undetected because many people have <a href="https://meetpositives.com/blog/asymptomatic-herpes-why-most-people-never-know-they-have-it">no recognizable symptoms</a> — a pattern familiar to anyone living with a chronic STI.</p>
<p>Without routine testing, syphilis quietly progresses through stages, eventually causing serious neurological and cardiovascular damage. Early detection is the entire ballgame here.</p>

<blockquote>"Syphilis is curable. The barrier isn't medicine — it's access. When cost disappears, people actually come in." — paraphrased from public health officials commenting on free clinic models across Texas</blockquote>

<h2>Why Free Care Changes Everything</h2>
<p>Cost is one of the most consistent reasons people delay or skip sexual health screenings. A 2023 analysis published by the <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166201/" target="_blank" rel="noopener noreferrer">National Institutes of Health</a> confirmed that financial barriers — even modest out-of-pocket costs — significantly reduce STI testing rates among uninsured and underinsured adults.</p>
<p>Texas has one of the highest uninsured rates in the nation. Remove the cost, and you remove one of the biggest reasons people put off getting tested until something feels wrong — which is often too late for the easiest intervention.</p>
<p>If you've ever delayed a test because of what it might cost, or because navigating insurance felt like a full-time job, this kind of clinic exists specifically for you. And if you're curious how <a href="https://meetpositives.com/blog/condoms-antivirals-prep-layering-protection-that-works">layered protection strategies</a> fit into your overall sexual health plan, that's exactly the conversation these clinics are equipped to have.</p>

<h2>The Bigger STI Picture You Need to See</h2>
<p>Syphilis doesn't exist in a vacuum. The same social and structural conditions driving syphilis upward — reduced public health funding, gaps in sex education, stigma that keeps people from getting tested — affect every STI on the map. According to the <a href="https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)" target="_blank" rel="noopener noreferrer">World Health Organization</a>, more than 1 million STIs are acquired globally every single day.</p>
<p>For our community — people living with HSV, HIV, HPV, or hepatitis — this isn't background noise. It's the environment we date, love, and make health decisions inside of. A syphilis co-infection can complicate treatment plans and increase HIV transmission risk. Knowing your full status, across all infections, is part of staying well.</p>
<p>We've covered the <a href="https://meetpositives.com/blog/sti-statistics-facts-2026">latest STI statistics and what they mean for you</a> in depth — and the trend lines demand attention, not panic, but definitely action.</p>

<h2>How to Find Free or Low-Cost Testing Near You</h2>
<p>If you're not in Austin, you're not out of options. Federally Qualified Health Centers (FQHCs) operate on sliding-scale fees nationwide. Planned Parenthood locations in many states offer low- or no-cost STI testing. The CDC's GetTested tool at gettested.cdc.gov lets you search by zip code.</p>
<p>If you're in Texas specifically, contact your county health department directly — many have funded programs that never get enough public attention because they're under-resourced and under-publicized.</p>

<p>Here's the bottom line for anyone in the MeetPositives community: syphilis is curable, but only if it gets diagnosed. The Austin clinic's free care model is a blueprint that should exist everywhere — and until it does, using every tool available to you, including free local clinics, telehealth options, and at-home testing, is how we protect ourselves and the people we're intimate with. Your sexual health is worth the hour it takes to get tested. Don't let cost be the reason you wait.</p>

MP News

Austin Clinic Goes Free as Texas Syphilis Cases Surge

<p>Cervical cancer kills more than 300,000 women every year worldwide — and nearly 90% of those deaths happen in low- and middle-income countries. Nigeria just took a direct swing at that statistic. A targeted HPV vaccination campaign reached 26,000 girls across the country, with health stakeholders calling it a concrete step toward eliminating one of the most preventable cancers on the planet.</p>

<h2>What Actually Happened</h2>
<p>According to <a href="https://guardian.ng" target="_blank" rel="noopener noreferrer">The Guardian Nigeria</a>, the campaign mobilized public health officials, community leaders, and school systems to administer the HPV vaccine to girls — the demographic most at risk for developing cervical cancer decades down the line. Stakeholders emphasized that catching girls before sexual debut is when the vaccine does its best work.</p>
<p>Nigeria carries one of the heaviest cervical cancer burdens in sub-Saharan Africa. The <a href="https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer" target="_blank" rel="noopener noreferrer">World Health Organization</a> estimates that Nigeria records over 14,000 new cervical cancer cases annually, with more than 8,000 deaths — numbers that dwarf those of wealthier nations with established immunization infrastructure.</p>

<h2>Why 26,000 Is Both a Win and a Wake-Up Call</h2>
<p>Let's be honest: 26,000 girls vaccinated sounds impressive until you remember that Nigeria has a population of over 220 million. The country needs to reach millions of girls to bend the cancer curve in any meaningful direction.</p>
<p>That doesn't diminish this campaign. It signals that the infrastructure is moving, that local governments and health advocates are buying in, and that scale is possible. But it also means the work is just beginning.</p>
<p>The <a href="https://www.cdc.gov/cancer/cervical/statistics/global.htm" target="_blank" rel="noopener noreferrer">CDC's global cervical cancer data</a> shows that countries with high HPV vaccination coverage — like Scotland, Australia, and Sweden — have seen near-elimination of HPV-related cervical disease in vaccinated cohorts. That outcome doesn't happen by accident. It takes years of sustained investment and political will.</p>

<blockquote>"The HPV vaccine is one of the most powerful cancer prevention tools we have. Reaching girls before exposure to the virus is where the real protection lies. Every campaign that expands coverage is a life saved, often 20 or 30 years from now." — Paraphrased from global reproductive health advocates at the Nigeria campaign launch, as reported by The Guardian Nigeria</blockquote>

<h2>The Science Behind the Vaccine Hasn't Changed — It's Still That Good</h2>
<p>HPV causes virtually all cervical cancers. The vaccine — whether Gardasil 9, Cervarix, or another approved formulation — protects against the high-risk strains responsible for the bulk of cases. We've covered the data on this extensively: the evidence that <a href="https://meetpositives.com/blog/hpv-vaccine-nearly-eliminates-cervical-cancer-deaths">HPV vaccination nearly eliminates cervical cancer deaths</a> in vaccinated populations keeps piling up.</p>
<p>Two doses before age 15 give the same immune response as three doses given later. That's the sweet spot public health campaigns like Nigeria's are aiming for — catch girls young, before first sexual contact, and the protection sticks.</p>
<p>It's also worth remembering that HPV doesn't only cause cervical cancer. It drives cancers of the throat, anus, penis, vulva, and vagina. If you've read our breakdown of how <a href="https://meetpositives.com/blog/hpv-vaccine-cuts-cancer-risk-in-men-by-half">the HPV vaccine cuts cancer risk in men by 50%</a>, you know this is not just a women's health issue.</p>

<h2>What This Means If You're Already Living with HPV</h2>
<p>If you're part of the MeetPositives community and you're living with HPV, this story hits differently. You understand — probably better than most — how quietly this virus moves through populations, how little warning it gives, and how much stigma gets attached to a diagnosis that is, statistically speaking, nearly universal in sexually active adults.</p>
<p>You can't undo a past infection with a vaccine. But campaigns like this one in Nigeria mean that future generations may never face the diagnosis conversation you've had to have. That matters. Prevention at population scale is how we get from where we are now to somewhere better.</p>
<p>If you're uncertain about your own HPV status, your partners' risk, or how to talk about this — our guide on <a href="https://meetpositives.com/blog/hpv-vaccine-slashing-cervical-cancer-deaths-data">the data behind HPV vaccination and cervical cancer deaths</a> is a strong place to start.</p>

<h2>The Bigger Pattern Worth Watching</h2>
<p>Nigeria's campaign doesn't exist in isolation. The WHO's global strategy aims to vaccinate 90% of girls against HPV by age 15, screen 70% of women by age 35 and 45, and treat 90% of women with detected disease — all by 2030. That's an ambitious target, and the gap between ambition and reality in low-resource settings is real.</p>
<p>But momentum is real too. Gavi, the Vaccine Alliance, has supported HPV vaccine rollouts across dozens of countries. Prices have dropped. Supply chains have improved. And national campaigns like this one in Nigeria demonstrate that local health systems can execute.</p>
<p>Every girl vaccinated today is a potential cancer diagnosis that never happens in 2045. That's the timeline we're talking about — long, slow, and absolutely worth tracking.</p>

<p>For our community: prevention stories like this one remind us that the science around sexually transmitted infections keeps moving forward. Whether you're living with HPV, HSV, HIV, or hepatitis, you deserve accurate information without shame attached to it. This is what public health doing its job looks like — imperfect, incremental, and still worth celebrating.</p>

Nigeria Just Vaccinated 26,000 Girls Against HPV

<p>If you got the HPV vaccine, your odds of dying before your 30th birthday just dropped to nearly zero. That's not marketing copy — that's what the data actually show, and it's a finding worth sitting with for a moment.</p>

<h2>What the Research Actually Found</h2>
<p>The study, reported by The Naked Scientists and drawing on large-scale population data from HPV vaccination programs, tracked mortality outcomes in people who received the HPV jab versus those who didn't. The results were striking: vaccinated individuals showed a mortality risk approaching zero before age 30.</p>

<p>HPV — human papillomavirus — is the most common sexually transmitted infection in the United States. The <a href="https://www.cdc.gov/hpv/index.html" target="_blank" rel="noopener noreferrer">CDC estimates that nearly 80 million Americans are currently infected</a>, and about 14 million new infections occur every year. Most people clear the virus without ever knowing they had it. But certain high-risk strains drive cancers of the cervix, throat, anus, penis, vagina, and vulva — cancers that kill tens of thousands of people annually.</p>

<p>The vaccine interrupts that chain before it starts. And now we have mortality data to prove just how completely it does that.</p>

<h2>Why the "Before 30" Window Matters So Much</h2>
<p>HPV-related cancers tend to develop slowly — often over a decade or more after initial infection. Cervical cancer, for example, can take 10 to 15 years to progress from initial HPV infection to invasive disease. So why does the mortality benefit appear so sharply before age 30?</p>

<p>Two reasons. First, vaccinated populations simply don't accumulate the persistent high-risk HPV infections that seed cancer. Second, some HPV-related complications — including rare but deadly cases of recurrent respiratory papillomatosis and aggressive cervical disease in younger patients — get eliminated almost entirely when vaccination happens early.</p>

<p>The <a href="https://www.nih.gov/news-events/news-releases/nih-funded-study-finds-hpv-vaccination-dramatically-reduces-cervical-cancer-rates" target="_blank" rel="noopener noreferrer">NIH has previously funded research confirming that HPV vaccination dramatically reduces cervical cancer rates</a>, and this new mortality analysis builds directly on that foundation. The picture is now clearer: vaccination doesn't just reduce cancer incidence — it saves young lives.</p>

<blockquote>"What we're seeing is essentially a vaccine that, when administered at the recommended age, removes an entire category of premature death from the table. That is an extraordinary public health outcome." — paraphrased from commentary by researchers in the Naked Scientists report on HPV vaccination outcomes</blockquote>

<h2>This Is What Prevention Actually Looks Like</h2>
<p>We talk a lot about treatment in the STI space — antivirals, suppressive therapy, transmission reduction. Treatment matters enormously. But the HPV vaccine is a reminder of what prevention at its most powerful looks like: you take a shot, and a whole cluster of cancers essentially disappears from your future.</p>

<p>Compare that to where we are with herpes, HIV, or hepatitis — conditions where we're still fighting hard for better treatments, better vaccines, and less stigma. We've been tracking the <a href="https://meetpositives.com/blog/hpv-vaccine-nearly-eliminates-cervical-cancer-deaths">HPV vaccine's near-elimination of cervical cancer deaths</a> for a while now, and this mortality data is the logical next chapter of that story.</p>

<p>The vaccine works. Emphatically. The data have been saying so for years, and now they're saying it louder.</p>

<h2>Who Still Needs This Vaccine — and Who Might Have Missed It</h2>
<p>The HPV vaccine (Gardasil 9 in the U.S.) is recommended by the CDC for preteens at age 11 or 12, but it's approved for use up to age 45. If you're in the MeetPositives community and you're living with HSV, HIV, or hepatitis, your immune system may already be working harder than average. Adding an HPV co-infection — particularly a persistent high-risk strain — is a burden worth preventing.</p>

<p>If you never received the vaccine and you're under 45, talk to your doctor or a sexual health clinic about whether you're a candidate. <a href="https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer" target="_blank" rel="noopener noreferrer">The WHO recommends vaccination as a primary strategy for eliminating cervical cancer globally</a>, and access has expanded in many countries through national programs.</p>

<p>People living with HIV are at significantly elevated risk for persistent HPV infection and HPV-related cancers. If that's you, this vaccine isn't optional background noise — it's a direct line of defense.</p>

<h2>What This Means for the Conversation Around STIs and Stigma</h2>
<p>Here's the part that doesn't get said enough: HPV stigma is real, and it does damage. People who test positive for high-risk HPV strains often spiral into shame and fear that far outweighs the actual clinical picture — especially when the virus clears on its own, as it does in the majority of cases.</p>

<p>The vaccine data we keep accumulating don't just save lives. They reframe the conversation. When we can point to near-zero mortality in vaccinated populations, we can also start dismantling the panic around HPV exposure and redirect energy toward prevention and early screening instead.</p>

<p>We've written about <a href="https://meetpositives.com/blog/hpv-vaccine-cuts-cancer-risk-in-men-by-half">how the HPV vaccine cuts cancer risk in men by 50%</a>, and the research keeps building. Every new data point is another argument against the silence that lets this virus — and the stigma around it — do more harm than it should.</p>

<p>If you're part of this community, you already know what it's like to carry a diagnosis that other people don't fully understand. You know the weight of that. The HPV vaccine doesn't erase stigma overnight — but it does prove, in hard numbers, that science moves faster than fear when we let it. Get vaccinated if you haven't. Tell the people you care about. And keep showing up for each other the way you do here.</p>

HPV Vaccine Recipients Have Near-Zero Risk of Dying Before 30

<p>More than <a href="https://www.cdc.gov/herpes/data-research/index.html" target="_blank" rel="noopener noreferrer">500 million people worldwide</a> live with genital herpes — and for decades, the best medicine could offer was "manage it, don't cure it." A new wave of vaccine research is finally starting to look like something more than hope.</p>

<h2>What the Prime-and-Pull Strategy Actually Does</h2>

<p>Most vaccines work by teaching your immune system to recognize a pathogen and attack it if it shows up later. The prime-and-pull approach does something different — and frankly, smarter when it comes to herpes.</p>

<p>"Priming" refers to giving the immune system an initial vaccine that trains it to produce herpes-specific T cells. "Pulling" means drawing those T cells directly into the genital tissue — the exact spot where HSV-2 hides and reactivates. That's the key twist. It's not enough to have immune cells circulating in your blood. For herpes, you need them stationed at the site of infection.</p>

<p>This matters because HSV-2 establishes latency in the sacral ganglia and reactivates locally. Standard immune surveillance often misses it. Getting T cells to <em>live</em> in genital tissue — essentially setting up a permanent watch post — is the strategic difference this method is chasing.</p>

<h2>What the Research Actually Found</h2>

<p>The research, reported by <em>Medical Xpress</em> and drawing on work in preclinical models, showed that animals receiving the prime-and-pull regimen developed strong, lasting populations of tissue-resident memory T cells (TRM cells) in genital tissue. These TRM cells didn't just pass through — they stayed, and they responded rapidly when the virus tried to reactivate.</p>

<p>The result: significantly reduced viral shedding and lesion formation compared to controls.</p>

<blockquote>"The goal is to have immune cells present at the site before the virus can establish a foothold. Tissue-resident memory T cells are exactly what we need for that kind of local, sustained protection." — paraphrased from lead researchers on the prime-and-pull vaccine approach</blockquote>

<p>Viral shedding — the process where HSV sheds from the skin even without visible symptoms — is one of the primary drivers of transmission. Cutting shedding doesn't just protect the person vaccinated. It changes the transmission math entirely.</p>

<p>For more context on why better HSV detection and suppression tools matter beyond just symptoms, read our piece on <a href="https://meetpositives.com/blog/why-better-genital-herpes-tests-matter">why better genital herpes tests matter for you</a>.</p>

<h2>Why This Approach Is Different From Past Failures</h2>

<p>Herpes vaccine research has a long, frustrating history. Candidates from Genocea, GlaxoSmithKline, and others generated excitement and then collapsed in late-stage trials. The pattern stung the HSV community — and rightfully so.</p>

<p>What went wrong before? Largely, those vaccines focused on generating antibodies. Antibodies are great for many viruses. But HSV spreads cell-to-cell and hides in neurons. Antibodies can't get in there. T cells — especially the tissue-resident kind — can.</p>

<p>The prime-and-pull method is mechanistically aligned with how HSV actually behaves, which is why immunologists are paying attention. This isn't just tweaking an old formula. It's a fundamentally different immune target.</p>

<p>We've covered related momentum in this space before — including the <a href="https://meetpositives.com/blog/dual-target-herpes-vaccine-strategy-shows-promise">dual-target herpes vaccine strategy</a> that researchers have been exploring, and <a href="https://meetpositives.com/blog/yale-two-pronged-herpes-vaccine-approach">Yale's two-shot herpes vaccine approach</a> that drew serious attention from the immunology world. The field is genuinely moving.</p>

<h2>Where This Research Stands Right Now</h2>

<p>Let's be clear: this is preclinical research. It has not yet been tested in human trials. The jump from animal models to human efficacy is where many promising candidates have stumbled before.</p>

<p>But the mechanistic logic is sound, the durability data from animal studies is encouraging, and the scientific community is taking this seriously. <a href="https://www.niaid.nih.gov/diseases-conditions/herpes-simplex-virus" target="_blank" rel="noopener noreferrer">The NIH's National Institute of Allergy and Infectious Diseases</a> has flagged HSV vaccine development as an active research priority, and funding in this space has grown in recent years.</p>

<p>The question isn't whether a protective herpes vaccine is theoretically possible. The immune system <em>can</em> control HSV — people with healthy immune function do it constantly. The question is whether we can reliably engineer that response in anyone, including people who are newly exposed.</p>

<p>According to <a href="https://www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus" target="_blank" rel="noopener noreferrer">the World Health Organization</a>, HSV-2 infects roughly 13% of the global population aged 15–49. A vaccine with even partial efficacy at population scale would represent a massive shift in sexual health outcomes worldwide.</p>

<h2>What This Means for People Living with Herpes Now</h2>

<p>If you're reading this on MeetPositives, you're probably not here for abstract science updates. You want to know: does this change anything for me, today?</p>

<p>Honestly? Not yet. No human trials, no timeline, no approval date. The road from "promising animal data" to "vaccine at your doctor's office" typically takes a decade or more — and that's when everything goes right.</p>

<p>What this research <em>does</em> change is the quality of the scientific conversation. The field is no longer asking "can a herpes vaccine work?" It's asking "which immune mechanism is the right target, and how do we optimize delivery?" That's a much better question to be arguing about.</p>

<p>For those of us living with HSV right now, the tools we have — antiviral suppression therapy, barrier methods, honest communication with partners — remain the most effective ways to reduce transmission risk and protect our health. None of that changes while we wait for a vaccine that actually works.</p>

<p>And while the science catches up, the emotional weight of an HSV diagnosis doesn't disappear on its own. If you're still working through what a diagnosis means for your dating life and relationships, our community has real stories and practical guidance — including how <a href="https://meetpositives.com/blog/how-people-with-herpes-rebuilt-confidence-in-dating">people with herpes have rebuilt their confidence in dating</a>.</p>

<p>We'll keep watching this research closely. When human trials begin, you'll hear about it here first.</p>

Prime-and-Pull Herpes Vaccine Shows Lasting Protection

<p>Half a billion people worldwide carry HSV-2, and for decades the scientific community has failed to deliver a vaccine that actually works. Now, a dual-target strategy — one that hits herpes from two immunological angles at once — is generating real excitement among virologists and the people who've been waiting the longest for a breakthrough.</p>

<h2>What the Dual-Target Approach Actually Does</h2>
<p>Traditional herpes vaccine attempts have largely gone after a single viral protein. The problem? HSV is extraordinarily good at hiding from the immune system, cloaking itself inside nerve cells and evading single-target antibody responses.</p>
<p>The new strategy targets two distinct components of the virus simultaneously — forcing the immune system to mount a broader, harder-to-evade defense. Researchers found that combining antibody-driven immunity with T-cell activation produced significantly stronger protection in preclinical models than either approach alone.</p>
<p>Think of it like a two-lock security system. Breaking one lock doesn't get you in anymore.</p>

<h2>Who's Behind the Research</h2>
<p>The work builds on a growing wave of dual-mechanism vaccine science being explored at institutions including the <a href="https://www.niaid.nih.gov/diseases-conditions/herpes-simplex-virus" target="_blank" rel="noopener noreferrer">National Institute of Allergy and Infectious Diseases (NIAID)</a>, which has long flagged HSV vaccine development as a priority research area.</p>
<p>This latest research, reported by Bioengineer.org, connects to a broader scientific moment. We've also covered how <a href="https://meetpositives.com/blog/uc-irvine-4m-nih-grant-hope-for-herpes-vaccine">UC Irvine secured a $4 million NIH grant</a> specifically to pursue herpes vaccine innovation — a signal that federal funding is finally catching up with public need.</p>
<p>The dual-target model appears to address a failure mode that has sunk previous candidates: vaccines that generated antibodies but couldn't stop viral shedding or reactivation in animal models.</p>

<h2>Why Previous Herpes Vaccines Have Failed</h2>
<p>This matters because the graveyard of failed herpes vaccines is long. GlaxoSmithKline's Herpevac trial — one of the most high-profile attempts — showed zero efficacy in men and limited, ultimately insufficient protection in women, despite years of development and significant investment.</p>
<p>The core challenge is HSV's ability to establish latency in the dorsal root ganglia — nerve clusters near the spine — where it sits dormant and largely invisible to circulating immune cells. A vaccine has to do more than prevent initial infection; it has to suppress reactivation too.</p>
<p>According to <a href="https://www.cdc.gov/herpes/index.html" target="_blank" rel="noopener noreferrer">CDC estimates</a>, roughly 1 in 6 Americans between the ages of 14 and 49 has HSV-2. Global <a href="https://www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus" target="_blank" rel="noopener noreferrer">WHO data</a> puts the worldwide HSV-2 burden at approximately 491 million people aged 15–49. A working vaccine would be one of the most significant sexual health advances in a generation.</p>

<blockquote>"The immune correlates of protection for HSV-2 are not fully understood, but evidence increasingly points to the need for both robust antibody responses and strong T-cell-mediated immunity to control the virus effectively." — paraphrased from NIAID HSV research priority documentation</blockquote>

<h2>What This Means Right Now — Honestly</h2>
<p>Let's be direct: this is preclinical research. That means animal models, not human trials. The road from a promising lab result to an FDA-approved vaccine is long, expensive, and littered with candidates that looked great in mice and stumbled in humans.</p>
<p>But the direction of this science is meaningful. Multiple research groups are now converging on the same core insight — that single-target approaches aren't enough. When independent teams start arriving at the same conclusion through different methods, that's when confidence in a hypothesis starts to build.</p>
<p>For those of us living with herpes, it's also worth keeping an eye on the drug pipeline alongside the vaccine pipeline. <a href="https://meetpositives.com/blog/new-herpes-drug-cuts-transmission-by-94-what-abi-5366-trial-results-mean">ABI-5366's trial results showing a 94% reduction in transmission</a> represent a separate but equally important track — one that's closer to clinical reality right now.</p>

<h2>The Bigger Picture for the HSV Community</h2>
<p>For years, herpes research was underfunded relative to its actual public health impact. The stigma attached to the diagnosis made it politically easier to deprioritize — as if the 500 million people living with HSV-2 somehow deserved less scientific urgency than other chronic viral conditions.</p>
<p>That's shifting. NIH funding is moving. Academic centers are publishing. And dual-mechanism thinking is becoming the new baseline assumption in the field.</p>
<p>If you're newly diagnosed and trying to make sense of what your future looks like, know that the science is moving faster than it ever has. And while a vaccine isn't here yet, tools for managing, disclosing, and <a href="https://meetpositives.com/blog/how-people-with-herpes-rebuilt-confidence-in-dating">rebuilding your confidence in dating with herpes</a> absolutely are.</p>
<p>We'll keep tracking every meaningful development in this research space and reporting it back to you without the hype or the clinical distance. This community deserves real information — and real hope grounded in actual science.</p>

Dual-Target Herpes Vaccine Strategy Shows Real Promise

<p>You've been on two great dates. There's real chemistry. And now that quiet dread starts creeping in — <em>when do I tell them?</em> The disclosure conversation is the moment most people with herpes, HIV, HPV, or hepatitis dread more than any other part of dating. Not the diagnosis itself. Not the medications. The conversation. And yet, most of the fear around it comes from imagining the worst version of something that, in reality, often goes better than you'd expect.</p>

<h2>There's No Perfect Moment — But There Is a Right Window</h2>

<p>One of the most common questions in our community is some version of: "How long should I wait before telling someone?" The honest answer is that timing matters, but not in the way most people think.</p>

<p>Disclosing too early — like in your opening message on a dating app — can feel clinical and put pressure on a connection that hasn't had a chance to breathe yet. Waiting too long — say, after you've both started developing strong feelings — can make the other person feel like information was withheld, which adds an unnecessary trust hurdle to an already delicate conversation.</p>

<p>The window that tends to work best is <strong>before you're physically intimate, but after you've established enough comfort that the conversation feels human rather than transactional</strong>. That might be after the second or third date. It might be during a phone call before you've even met in person. You'll know when it feels like a real connection, rather than an audition.</p>

<p>If you're still building the confidence to even get to that point, <a href="https://meetpositives.com/blog/how-to-start-dating-again-after-an-std-diagnosis">starting to date again after a diagnosis</a> has its own learning curve — and that's completely normal.</p>

<h2>What to Actually Say (Without Over-Explaining)</h2>

<p>Most people rehearse the disclosure conversation as if they're preparing a legal brief. They over-explain, apologize excessively, and bury the actual information under so much context that the other person doesn't know how to respond.</p>

<p>Keep it simple and matter-of-fact. Something like:</p>

<blockquote>"Before things go any further, I want to be honest with you about something. I have herpes [or HSV-2, or HIV, whatever applies]. I manage it [with antivirals / with medication / etc.], and I think it's important you have that information so we can make decisions together."</blockquote>

<p>That's it. You don't need to apologize for your status. You don't need to deliver a medical lecture. You're treating them — and yourself — like adults who can have an honest conversation.</p>

<p>What you <em>should</em> be ready to do is answer questions calmly. Have some basic facts on hand. For example, the <a href="https://www.cdc.gov/std/herpes/stdfact-herpes.htm" target="_blank" rel="noopener noreferrer">CDC notes that genital herpes affects roughly 1 in 6 people aged 14 to 49 in the United States</a> — that's a number worth knowing, because it helps frame your disclosure as a common health reality rather than something shocking.</p>

<p>For HIV specifically, being able to explain what "undetectable = untransmittable" (U=U) means can completely change the conversation. <a href="https://www.cdc.gov/hiv/risk/art/index.html" target="_blank" rel="noopener noreferrer">The CDC confirms that people with HIV who maintain an undetectable viral load through treatment have effectively no risk of sexually transmitting the virus</a>.</p>

<h2>How to Handle the Reaction — Whatever It Is</h2>

<p>Some people will respond with warmth and curiosity. Some will need time to process. Some will pull back. All of those reactions are valid, and none of them define your worth.</p>

<p>If someone needs a few days to think about it, give them space without chasing. A response like "Take your time, I'm happy to answer any questions when you're ready" keeps the door open without applying pressure.</p>

<p>If someone reacts with cruelty or disgust, that's genuinely useful information about who they are — not about who you are. That kind of reaction stings, and it's okay to let it sting. But it's also a clean ending to something that wouldn't have worked anyway.</p>

<p><a href="https://meetpositives.com/blog/how-to-handle-rejection-after-telling-someone-you-have-herpes">Handling rejection after disclosure</a> is its own emotional skill, and one worth developing — because even in the best circumstances, not every disclosure leads to a relationship, and that's true for people without STIs too.</p>

<h2>The Psychology Behind Why This Feels So Hard</h2>

<p>Here's something worth understanding: the anxiety around disclosure is rarely about the actual conversation. It's about internalized stigma — the belief, absorbed from a culture that treats STIs as shameful, that your diagnosis makes you less worthy of connection.</p>

<p>Research published in <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696762/" target="_blank" rel="noopener noreferrer">the journal <em>Sexually Transmitted Infections</em> found that stigma, not symptoms, is the primary driver of psychological distress after an STI diagnosis</a>. The condition itself is often manageable. The shame is what does the real damage.</p>

<p>Recognizing that the fear is rooted in stigma — rather than in anything that's actually wrong with you — won't eliminate the nerves, but it does change how you hold them. You're not confessing a flaw. You're sharing a health fact with someone you trust enough to be close to.</p>

<h2>Practicing Before the Real Conversation</h2>

<p>This sounds obvious, but most people skip it: practice saying the words out loud before you say them to a partner.</p>

<p>Say it in the mirror. Say it to a trusted friend. Say it into a voice memo on your phone. The first time a disclosure sentence leaves your mouth out loud, it often sounds more alarming than it does in your head — and that's precisely why practicing matters. By the time you're sitting across from someone you care about, the words will feel familiar rather than explosive.</p>

<p>You can also think through likely follow-up questions in advance. "Is it contagious right now?" "Does it affect having kids?" "What does treatment look like?" Knowing your answers — not perfectly, but comfortably — gives you a sense of grounded confidence that reads well to the other person.</p>

<p>If you're newer to all of this, the broader guide on <a href="https://meetpositives.com/blog/herpes-dating-what-to-say-when-you-disclose-hsv">what to say when you disclose HSV</a> goes deeper on specific language and phrasing that tends to land well.</p>

<p>Here in the MeetPositives community, you're surrounded by people who've had this conversation — some of them dozens of times — and who've built real, lasting relationships on the other side of it. The disclosure talk is not the end of something. For a lot of people, it's the moment a real connection actually begins.</p>

STD Dating & Relationships

The Disclosure Talk: When and How to Tell Someone You Have an STI

<p>Getting the HPV shot before your 17th birthday may effectively take cervical cancer death off the table. That's not a hopeful spin — that's the finding from a large-scale Swedish study that tracked women over decades and found mortality risk dropped to virtually nothing for those vaccinated early.</p>

<h2>What the Study Actually Found</h2>

<p>Researchers analyzed data from over 1.6 million women in Sweden, tracking outcomes across vaccinated and unvaccinated groups. The results, published in <a href="https://www.nejm.org/" target="_blank" rel="noopener noreferrer"><em>The New England Journal of Medicine</em></a>, show that women who received the HPV vaccine before age 17 had a near-zero rate of cervical cancer death.</p>

<p>The risk didn't just drop — it nearly disappeared. Women vaccinated between ages 17 and 30 also saw significant reductions, though not as dramatic as the younger cohort.</p>

<p>This is population-level evidence. Not a small trial. Not preliminary data. Decades of real outcomes from real women.</p>

<h2>Why Timing Matters So Much</h2>

<p>HPV spreads through skin-to-skin sexual contact, and most people acquire it within their first few years of sexual activity. The vaccine works best before that exposure happens.</p>

<p>Dr. Jiayao Lei at the Karolinska Institutet in Stockholm, one of the study's lead researchers, emphasized that vaccination before sexual debut gives the immune system time to build full protection against the high-risk strains — primarily HPV 16 and 18 — that drive most cervical cancers.</p>

<blockquote>"The results clearly show that HPV vaccination in early adolescence was associated with a substantially reduced risk of cervical cancer," Dr. Lei told reporters following the study's publication. "The earlier the vaccination, the greater the benefit."</blockquote>

<p>This tracks with what the <a href="https://www.cdc.gov/hpv/parents/vaccine.html" target="_blank" rel="noopener noreferrer">CDC has long recommended</a>: vaccination at ages 11 to 12, with catch-up through age 26 for those who missed it.</p>

<h2>What This Means if You Have HPV Right Now</h2>

<p>Many people in this community already have HPV. Some were diagnosed before a vaccine was available. Some weren't vaccinated in time. That's not a failure — it's just reality.</p>

<p>If you're living with HPV, this study doesn't change your current situation, but it does two important things. First, it confirms the vaccine works — which strengthens the case for vaccinating younger family members in your life. Second, it reinforces why consistent cervical screening still matters for you.</p>

<p>Regular Pap smears and HPV co-tests catch precancerous changes before they become cancer. The vaccine prevents infection; screening catches what slips through. You need both arms of that strategy if you're already positive.</p>

<p>We've covered the data on <a href="https://meetpositives.com/blog/hpv-vaccine-slashing-cervical-cancer-deaths-data">how the HPV vaccine is slashing cervical cancer deaths</a> before — but this Swedish study is the most definitive mortality data we've seen yet.</p>

<h2>The Bigger Picture: A Cancer We Could Actually Wipe Out</h2>

<p>Cervical cancer kills approximately <a href="https://www.who.int/news-room/fact-sheets/detail/cervical-cancer" target="_blank" rel="noopener noreferrer">342,000 women globally every year</a>, according to the World Health Organization. Nearly all of those deaths link back to persistent HPV infection.</p>

<p>The science is blunt: this is a preventable cancer death toll. Not theoretically preventable — actually preventable, with a vaccine that's been available since 2006.</p>

<p>The barrier isn't the biology. It's access, misinformation, and the kind of stigma that follows anything connected to sexual health. We know that stigma well here.</p>

<p>And yet the data keeps coming in. Sweden's vaccination rates are high, which is exactly why their researchers can now show us what near-elimination actually looks like in practice.</p>

<h2>Talking to People in Your Life About the Vaccine</h2>

<p>If you have kids, younger siblings, nieces, nephews, or friends with teenagers — this study gives you something real to point to. Not fear-based messaging. Just evidence.</p>

<p>The conversation doesn't have to be awkward. You don't have to disclose your own status. You can simply say: there's a vaccine that drops cervical cancer death risk to near zero, and the window to get maximum benefit is before 17.</p>

<p>For those navigating these conversations while managing their own diagnosis, our piece on <a href="https://meetpositives.com/blog/hpv-vaccine-cuts-cervical-cancer-risk-near-zero">how the HPV vaccine cuts cervical cancer risk to near zero</a> breaks down the numbers in plain language worth sharing.</p>

<p>If you're wondering how to talk about sexual health more broadly in your relationships, we also have a guide on <a href="https://meetpositives.com/blog/hpv-vaccine-cuts-cancer-risk-in-men-by-half">how the HPV vaccine cuts cancer risk in men by 50%</a> — a reminder this isn't just a women's health story.</p>

<h2>Here at MeetPositives, This Hits Different</h2>

<p>Our community carries a particular weight when this kind of research drops. Some of us got HPV before we knew what to watch for. Some of us were never told the vaccine existed until it was too late for the early-adolescent window. Some of us are still waiting on biopsy results.</p>

<p>We don't live in a world of theoretical risk. We live with real diagnoses, real screenings, and real conversations with doctors who may or may not take our concerns seriously.</p>

<p>So when science delivers a finding this clear — that a single intervention, given early enough, can reduce cervical cancer mortality to near zero — we should sit with that. Not with guilt about what we didn't know sooner, but with purpose about what we can do now: get screened, advocate for the people around us, and refuse to let stigma be the reason someone else doesn't get protected.</p>

<p>The vaccine works. The evidence is in. The only question left is who gets access to it — and who in your life you might help get there.</p>

HPV Vaccine Nearly Eliminates Cervical Cancer Deaths

<h2>A Major Step Forward in Herpes Research</h2><p>If you're living with genital herpes, you know how much the day-to-day reality — the outbreaks, the conversations, the emotional weight — can shape your life. That's why news out of the University of California, Irvine is genuinely exciting: a researcher there has been awarded <strong>nearly $4 million in NIH funding</strong> to develop a <strong>therapeutic vaccine targeting genital herpes (HSV-2)</strong>. This isn't a distant dream. It's funded, focused science moving in your direction.</p><p>For the more than <a href="https://www.cdc.gov/herpes/index.html" target="_blank" rel="noopener noreferrer">500 million people worldwide estimated to be living with HSV-2</a>, according to the CDC, this kind of research investment is more than a headline — it's a reason for real, grounded hope.</p><h2>What Is a Therapeutic Vaccine — and How Is It Different?</h2><p>Most of us grew up thinking of vaccines as something you get <em>before</em> you're exposed to a virus — like the flu shot or the HPV vaccine. A <strong>therapeutic vaccine</strong> works differently. Rather than preventing infection in the first place, it's designed to help people who already have the virus manage it more effectively.</p><p>For HSV-2, the goal of a therapeutic vaccine would be to <strong>train your immune system to suppress the virus more powerfully</strong> — reducing the frequency and severity of outbreaks, and potentially lowering the risk of transmission to partners. In other words, it wouldn't cure herpes, but it could meaningfully change what living with it looks like day to day.</p><p>This approach is gaining traction in the scientific community. According to <a href="https://www.niaid.nih.gov/diseases-conditions/herpes-simplex-virus" target="_blank" rel="noopener noreferrer">the National Institute of Allergy and Infectious Diseases (NIAID)</a>, HSV-2 establishes a lifelong latent infection in nerve cells, which makes it particularly challenging for the immune system to fully control — and exactly why a vaccine designed to bolster that immune response could be so impactful.</p><h2>Why This UC Irvine Grant Matters</h2><p>NIH grants at this funding level — nearly $4 million — are highly competitive and signal serious institutional confidence in a researcher's approach. This investment means the work will have the resources to move through rigorous preclinical testing, helping scientists understand whether the vaccine candidate is safe, effective, and worth advancing toward human trials.</p><p>What makes this particularly promising is the growing body of innovative delivery and immune-targeting strategies being explored in HSV research. From <a href="https://meetpositives.com/blog/charcoal-delivery-system-herpes-control">novel delivery systems for herpes control</a> to antiviral compounds cutting transmission rates dramatically, the research pipeline for herpes has never been more active or more funded.</p><p>And this UC Irvine project joins that momentum. A therapeutic herpes vaccine could complement existing antiviral medications like valacyclovir, potentially giving people living with HSV-2 a more robust toolkit for managing their health and protecting their partners.</p><h2>What This Could Mean for the Herpes Community</h2><p>Let's be honest: the stigma around herpes often hurts far more than the virus itself. Breakthroughs like this matter not just medically, but emotionally. When high-profile, well-funded science takes genital herpes seriously, it sends a message to the broader public — and to people living with HSV — that <strong>this condition deserves real attention, real resources, and real solutions</strong>.</p><p>For those of us navigating dating and relationships with HSV-2, a therapeutic vaccine that could reduce outbreaks and transmission risk would be genuinely life-changing. It could ease the weight of disclosure conversations, reduce anxiety during intimate moments, and help normalize herpes as the manageable, common condition it truly is. If you're curious about what <a href="https://meetpositives.com/blog/new-herpes-drug-cuts-transmission-by-94-what-abi-5366-trial-results-mean">the latest herpes transmission-reduction research</a> looks like right now, there's already reason to feel encouraged even before a vaccine arrives.</p><h2>Where Things Stand — and What to Expect Next</h2><p>It's important to be realistic about timelines. A grant award marks the <em>beginning</em> of a long research process, not the finish line. Here's a general sense of what the road ahead looks like:</p><ul><li><strong>Preclinical research:</strong> The funded work will involve laboratory and animal model testing to evaluate safety and immune response.</li><li><strong>Phase I trials:</strong> If preclinical results are strong, the vaccine would move into early human safety trials.</li><li><strong>Phase II/III trials:</strong> Larger trials test effectiveness across broader populations.</li><li><strong>FDA review and approval:</strong> The final step before a vaccine becomes widely available.</li></ul><p>This process typically takes many years. But every major medical advancement starts exactly here — with a scientist, a question, and funding to pursue it seriously. According to <a href="https://pubmed.ncbi.nlm.nih.gov/" target="_blank" rel="noopener noreferrer">published HSV vaccine research on PubMed</a>, therapeutic immunization strategies have shown increasing promise in recent studies, building scientific confidence that the approach is viable.</p><h2>What You Can Do Right Now</h2><p>While the research unfolds, there are meaningful steps you can take today to manage your health and live fully with HSV-2:</p><ul><li><strong>Talk to your doctor</strong> about antiviral suppressive therapy, which can reduce outbreak frequency and lower transmission risk.</li><li><strong>Stay informed</strong> about emerging research — breakthroughs are happening faster than ever.</li><li><strong>Connect with community.</strong> Living with herpes doesn't have to feel isolating. Platforms like MeetPositives exist specifically so you can date, connect, and build relationships with people who understand your experience.</li><li><strong>Explore your own story.</strong> If you're newly navigating a diagnosis, resources like our guide on <a href="https://meetpositives.com/blog/just-diagnosed-with-herpes">what to do after a herpes diagnosis</a> can help you find your footing with compassion and clarity.</li></ul><h2>The Bottom Line: Science Is On Your Side</h2><p>The UC Irvine NIH grant for a therapeutic genital herpes vaccine is a powerful reminder that the scientific community is actively working to improve life for people living with HSV-2. It's not a cure today, but it represents real momentum — the kind that changes futures. You deserve to feel hopeful about what's coming. You also deserve to feel supported right now, exactly as you are. That's what MeetPositives is here for: a warm, judgment-free community where your diagnosis is never the whole story.</p><p>Stay curious. Stay connected. And know that the science is moving forward — for you.</p>

UC Irvine's $4M NIH Grant: Hope for a Herpes Vaccine

Practical dating advice for people living with herpes, HIV, HPV, and other STIs. Tips on disclosure, building confidence, writing your profile, and finding meaningful connections.

Dating Advice for Positive Singles | MeetPositives Blog

Dating Advice

Articles and advice for dating with herpes (HSV-1 and HSV-2). Learn how to disclose, build confidence, find HSV-positive partners, and navigate relationships with herpes.

Herpes Dating Tips & Advice | HSV Dating Articles | MeetPositives Blog

Herpes Dating

Honest advice on dating with an STI or STD. Articles on disclosure, stigma, building relationships, and finding love as a positive single.

STD Dating Advice & Tips for Positive Singles | MeetPositives Blog

STD Dating

Real success stories from people who found love, connection, and lasting relationships through MeetPositives. Proof that a positive diagnosis doesn't define your romantic life.

STI Dating Success Stories | Real Relationships | MeetPositives Blog

Success Stories

Articles on the emotional and mental health impact of an STI diagnosis. Coping strategies, stigma, self-worth, and rebuilding confidence while dating with herpes, HIV, or HPV.

Mental Health & STI Stigma | Coping After Diagnosis | MeetPositives Blog

Mental Health

Articles on STI symptoms, testing, and what to expect after a positive result. Covers herpes, HIV, HPV, hepatitis, and other conditions in plain language.

STI Symptoms & Testing Guides | Herpes, HIV, HPV, Hepatitis | MeetPositives Blog

Symptoms & Testing

In-depth guides on living with herpes, HIV, HPV, and hepatitis. Covers transmission, treatment, dating, and community resources for positive singles.

STI Condition Guides | Herpes, HIV, HPV, Hepatitis | MeetPositives Blog

Condition Guides

Mental Health & Stigma

Articles on sexual health, safer intimacy, STI prevention, and building healthy relationships as a positive single. Honest, stigma-free education for adults.

Sexual Health & Safer Intimacy | STI Prevention & Education | MeetPositives Blog

Sexual Health

Sexual Health & Safer Intimacy

The latest STI research, awareness campaigns, treatment advances, and public health news. Stay informed on herpes, HIV, HPV, and hepatitis developments.

STI Research & Awareness | Latest News & Studies | MeetPositives Blog

Research

Research & Awareness

How to stay safe while dating online. Spot romance scams, verify identities, protect your privacy, and avoid catfishing when dating with an STI.

Online Dating Safety & Scam Prevention | MeetPositives Blog

Online Dating Protection

Everything new members need to know about MeetPositives — setting up your profile, finding matches, staying safe, and making the most of the platform.

Getting Started on MeetPositives | New Member Guide | MeetPositives Blog

Getting Started

Official news, platform updates, and announcements from MeetPositives. Stay up to date on new features, community milestones, and company news.

MeetPositives News & Platform Updates | MeetPositives Blog

Stories, perspectives, and voices from the MeetPositives community. Real members sharing their experiences with STI dating, disclosure, relationships, and more.

Community Posts & Member Voices | MeetPositives Blog

Community Posts

Guides and updates on MeetPositives app and website features. Learn how to use messaging, search, profile tools, verification, and more.

MeetPositives App & Site Features | How It Works | MeetPositives Blog

App Features

Articles on living well with an STI — mental health, physical wellness, relationships, self-care, and navigating everyday life as a positive single.

Which STDs Are Curable (and Which Are Permanent)? A Complete Guide

Popular Topics

Popular Tags

Communication